Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis

Cancer Research

Volumn 70, Issue 13, 2010, Pages 5337-5347

  Nguyen, Minh Hue ^a   Koinuma, Junkichi ^a   Ueda, Koji ^a,c   Ito, Tomoo ^b   Tsuchiya, Eiju ^c   Nakamura, Yusuke ^a   Daigo, Yataro ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c RIKEN   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; COMPLEMENTARY DNA; GLUTAMINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN CDCA5; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CANCER GROWTH; CELL ACTIVATION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CERCOPITHECUS AETHIOPS; COS CELLS; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHORYLATION; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION;

EID: 77954354935     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4372     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;58:71-96.
2. Schiller JH, Harrington D, Belani CP, et al, Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
3. Sozzi G. Molecular biology of lung cancer. Eur J Cancer 2001; 37:63-73.
4. Daigo Y, Nakamura Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg 2008;56: 43-53. (Pubitemid 351311467)
5. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192-205. (Pubitemid 36539569)
6. Kakiuchi S, Daigo Y, Tsunoda T, Yano S, Sone S, Nakamura Y. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 2003;1:485-99. (Pubitemid 36577045)
7. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004;13:3029-43. (Pubitemid 40045258)
8. Kikuchi T, Daigo Y, Ishikawa N, et al. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol 2006;28:799-805.
9. Taniwaki M, Daigo Y, Ishikawa N, et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 2006;29:567-75.
10. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 2003;63:7038-41. (Pubitemid 37413435)
11. Kato T, Daigo Y, Hayama S, et al. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res 2005;65:5638-46. (Pubitemid 40911164)
12. Furukawa C, Daigo Y, Ishikawa N, et al. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res 2005;65:7102-10. (Pubitemid 41161239)
13. Suzuki C, Daigo Y, Ishikawa N, et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res 2005;65:11314-25. (Pubitemid 41821688)
14. Ishikawa N, Daigo Y, Takano A, et al. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci 2006;97:737-45. (Pubitemid 43983786)
15. Takahashi K, Furukawa C, Takano A, et al. The neuromedin u-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res 2006;66:9408-19. (Pubitemid 44623637)
16. Hayama S, Daigo Y, Kato T, et al. Activation of CDCA1-2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 2006;66:10339-48. (Pubitemid 44799753)
17. Kato T, Hayama S, Yamabuki Y, et al. Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res 2007;13:434-42. (Pubitemid 46225347)
18. Suzuki C, Takahashi K, Hayama S, et al. Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol Cancer Ther 2007;6:542-51. (Pubitemid 46332456)
19. Hayama S, Daigo Y, Yamabuki T, et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res 2007;67: 4113-22. (Pubitemid 46815056)
20. Taniwaki M, Takano A, Ishikawa N, et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res 2007;13:6624-31. (Pubitemid 350206797)
21. Mano Y, Takahashi K, Ishikawa N, et al. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Sci 2007;98:1902-13. (Pubitemid 350002196)
22. Kato T, Sato N, Hayama S, et al. Activation of HJURP (Holliday Junction-Recognizing Protein) involved in the chromosomal stability and immortality of cancer cells. Cancer Res 2007;67:8544-53. (Pubitemid 47437429)
23. Kato T, Sato N, Takano A, et al. Activation of placenta specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clin Cancer Res 2008;14:2363-70. (Pubitemid 351551069)
24. Dunleavy EM, Roche D, Tagami H, et al. HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell 2009;137:485-97.
25. Hirata D, Yamabuki T, Ito T, et al. Involvement of epithelial cell transforming sequence 2 (ECT2) oncoantigen in lung and esophageal cancer progression. Clin Cancer Res 2009;15:256-66.
26. Sato N, Koinuma J, Fujita M, et al. Activation of WD repeat and HMG-box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer Res 2010;16:226-39.
27. Ishikawa N, Daigo Y, Yasui W, et al. ADAM8 as a novel serological and histochemical marker for lung cancer.Clin Cancer Res 2004;10: 8363-70.
28. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and transforming growth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005;65:9176-84.
29. Yamabuki T, Takano A, Hayama S, et al. Dickkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007;67:2517-25.
30. Ishikawa N, Takano A, Yasui W, et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007;67:11601-11.
31. Takano A, Ishikawa N, Nishino R, et al. Identification of Nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009;69:6694-703.
32. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007;98:1803-8.
33. Mizukami Y, Kono K, Daigo Y, et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008;99:1448-54.
34. Harao M, Hirata S, Irie A, et al. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer 2008; 123:2616-25.
35. Kono K, Mizukami Y, Daigo Y, et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 2009;100:1502-9.
36. Yokomine K, Senju S, Nakatsura T, et al. The forkhead box M1 transcription factor, as a possible immunotherapeutic tumor-associated antigen. Int J Cancer 2010;126:2153-63.
37. Rankin S, Ayad N, Meinke G, et al. Sororin, a substrate of anaphase-promoting complex, is required for sister chromatid cohesion in vertebrates. Mol Cell 2005;18:185-200. (Pubitemid 40503198)
38. Schmitz J, Watrin E, Lenart P, et al. Sororin is required for stable binding of cohesion to chromatid and for sister chromatid cohesion in interphase. Curr Biol 2007;17:630-6. (Pubitemid 46497795)
39. Sobin L, Wittekind C. Anonymous TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.
40. Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003;12:27-34. (Pubitemid 36255267)
41. Callagy G, Pharoah P, Chin SF, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005;205: 388-96. (Pubitemid 40253928)
42. Chin SF, Daigo Y, Huang HE, et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 2003;56:275-9.
43. Olsen JV, Blagoev B, Gnad F. Global, in vivo and site-specific phosphorylation dynamics in signaling networks. Cell 2006;127: 635-48.
44. Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001;276: 5836-40.
45. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004;68:320-44.
46. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40. (Pubitemid 32225829)
47. Ferrell JE, Jr. Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs. Trends Biochem Sci 1996;21:460-6.
48. Mansour SJ, Matten WT, Hermann AS, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265:966-70.
49. Smith RA, Dumas J, Adnane L, Wilhelm SM. Recent advances in the research and development of RAF kinase inhibitors. Curr Top Med Chem 2006;6:1071-89. (Pubitemid 44110921)
50. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 2002;23:40-5.